Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Acro Biotech Highlights Expanded Toxicology and Rapid Diagnostic Portfolio

By LabMedica International staff writers
Posted on 18 Nov 2025

Acro Biotech is presenting its extensive product range at MEDICA 2025 that includes approved drugs of abuse tests, women’s health related rapid tests, cardiac markers, tumor markers, among others.

Exhibiting at booth C40-5 in Hall 3, the company invites attendees to explore a portfolio spanning drugs of abuse (DOA) testing, fluorescence immunoassay (FIA) panels, and urine analysis. More...

On display are new DOA rapid tests for Scopolamine (SCOP), Citalopram (CIT), and Fentanyl (FYL), reflecting demand for broader toxicology coverage in hospital and occupational health workflows.

For laboratory medicine applications, the company’s booth features FIA tests covering cardiac and endocrine markers, including Troponin I/Myoglobin/CK‑MB (creatine kinase‑MB), Prolactin, and Vitamin D. Instrumentation on display includes the Apoti Plus Fluorescence Immunoassay Analyzer (1 Channel) for benchtop use, the AcrMove Up Handheld Fluorescence Immunoassay Analyzer for mobile testing, and the Optilyte Plus Urine Analyzer to support routine urinalysis.

The lineup also includes the Urine Cup for Multi‑Drug Testing aimed at streamlined specimen collection and rapid screening. At the company's booth, specialists will provide live demonstrations and discuss implementation to align with laboratory and near‑patient workflows across emergency care, toxicology, and chronic disease monitoring.

Related Links:
Acro Biotech


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
Pipette Calibration System
Artel PCS®
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Single Genetic Analysis Identifies Causes of Premature Ovarian Insufficiency

Premature ovarian insufficiency (POI) affects up to 3.5% of women and represents a major cause of infertility. In most cases, the underlying etiology remains unknown, making patient counseling and clinical... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.